These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 28391878)

  • 1. Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy.
    Koopal C; Marais AD; Westerink J; Visseren FL
    J Clin Lipidol; 2017; 11(1):12-23.e1. PubMed ID: 28391878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.
    Koopal C; Marais AD; Visseren FL
    Curr Opin Endocrinol Diabetes Obes; 2017 Apr; 24(2):133-139. PubMed ID: 28098593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.
    Smelt AH; de Beer F
    Semin Vasc Med; 2004 Aug; 4(3):249-57. PubMed ID: 15630634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.
    Corsetti JP; Sparks CE; Bakker SJL; Gruppen EG; Dullaart RPF
    Clin Biochem; 2018 Feb; 52():67-72. PubMed ID: 29157655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.
    Heidemann BE; Koopal C; Baass A; Defesche JC; Zuurbier L; Mulder MT; Roeters van Lennep JE; Riksen NP; Boot C; Marais AD; Visseren FLJ
    Clin Genet; 2022 Oct; 102(4):253-261. PubMed ID: 35781703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical and laboratory investigation of dysbetalipoproteinemia.
    Boot CS; Luvai A; Neely RDG
    Crit Rev Clin Lab Sci; 2020 Nov; 57(7):458-469. PubMed ID: 32255405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial dysbetalipoproteinemia: a genetically heterogenous disease caused by mutations of the ligand apolipoprotein E.
    Vermeer BJ; Frants RR; Havekes LM
    J Invest Dermatol; 1992 Jun; 98(6 Suppl):57S-60S. PubMed ID: 1588125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance involvement in prevalence of familial dysbetalipoproteinemia in ε2ε2 subjects by Bayesian network modeling.
    Corsetti JP; Love TM; Sparks CE; Bakker SJL; Dullaart RPF
    Clin Biochem; 2018 Sep; 59():31-36. PubMed ID: 29928902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysbetalipoproteinemia: an extreme disorder of remnant metabolism.
    Marais D
    Curr Opin Lipidol; 2015 Aug; 26(4):292-7. PubMed ID: 26103610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial dysbetalipoproteinemia in three patients with apoE 2*(Arg136-->Cys) gene variant.
    Vrablík M; Horínek A; Ceska R; Stulc T; Kvasnicka T
    Physiol Res; 2003; 52(5):647-50. PubMed ID: 14535841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance.
    Smit M; de Knijff P; van der Kooij-Meijs E; Groenendijk C; van den Maagdenberg AM; Gevers Leuven JA; Stalenhoef AF; Stuyt PM; Frants RR; Havekes LM
    J Lipid Res; 1990 Jan; 31(1):45-53. PubMed ID: 2313204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia.
    Solanas-Barca M; de Castro-Orós I; Mateo-Gallego R; Cofán M; Plana N; Puzo J; Burillo E; Martín-Fuentes P; Ros E; Masana L; Pocoví M; Civeira F; Cenarro A
    Atherosclerosis; 2012 Jun; 222(2):449-55. PubMed ID: 22481068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.
    de Knijff P; van den Maagdenberg AM; Frants RR; Havekes LM
    Hum Mutat; 1994; 4(3):178-94. PubMed ID: 7833947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.
    de Knijff P; van den Maagdenberg AM; Stalenhoef AF; Leuven JA; Demacker PN; Kuyt LP; Frants RR; Havekes LM
    J Clin Invest; 1991 Aug; 88(2):643-55. PubMed ID: 1864973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type III Hyperlipoproteinemia: Still Worth Considering?
    Blum CB
    Prog Cardiovasc Dis; 2016; 59(2):119-124. PubMed ID: 27481046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [From gene to disease; apolipoprotein E2 and familial dysbetalipoproteinemia].
    Smelt AH
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):157-9. PubMed ID: 12635547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
    Koopal C; Retterstøl K; Sjouke B; Hovingh GK; Ros E; de Graaf J; Dullaart RP; Bertolini S; Visseren FL
    Atherosclerosis; 2015 May; 240(1):90-7. PubMed ID: 25768710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease.
    Mahley RW
    Isr J Med Sci; 1996 Jun; 32(6):414-29. PubMed ID: 8682647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Lipoprotein Electrophoresis and Apolipoprotein E Genotyping in Investigating Dysbetalipoproteinemia.
    Ahmed F; El-Kadiki A; Gibbons S
    J Coll Physicians Surg Pak; 2017 Jun; 27(6):378-379. PubMed ID: 28689531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.